and overall survival (all P < .05). Multivariate analysis showed that PD-L1 + immune cells were an independent prognostic factor for overall (P = .001) and recurrence-free survival (P = .024). Notably, high stromal CD8 + TIL and PD-1 + TIL density were associated with poorer overall survival (P = .031 and P = .001, respectively). In the stroma,
and overall survival (all P < .05). Multivariate analysis showed that PD-L1 + immune cells were an independent prognostic factor for overall (P = .001) and recurrence-free survival (P = .024). Notably, high stromal CD8 + TIL and PD-1 + TIL density were associated with poorer overall survival (P = .031 and P = .001, respectively). In the stroma,
CD8
+ TIL density has strong positive association with PD-L1 + immune cells and PD-1 + TIL density (all P < .0001). These results suggested that an exhausted immune state occurred in the tumor stroma in UCB. Further clinical development of immunecheckpoint inhibitors may be effective for resectable patients with UCB. 
| INTRODUC TI ON
The prognosis and treatment of UCB have improved little since the 1980s. 1 Comprehensive molecular characterizations in recent genome-wide expression and sequencing studies have indicated several subtypes of bladder cancer. 2, 3 However, it is unclear whether improved tumor stratification based on these molecular classifications will provide clinical benefit by enhancing targeted therapy.
Interestingly, TCGA indicates UCB contains more somatic mutations than most common cancers, and may contain high levels of tumorspecific neoantigens. 4 BCG therapy exerts an antitumor effect in bladder cancer by activation of the immune system, indicating immune status may represent a target for and marker of effective anticancer immunotherapies in UCB.
5
Tumor progression is the product of crosstalk between different cell types within tumors. 6, 7 
| MATERIAL S AND ME THODS

| Patients and tissue specimens
| Immunohistochemistry
Formalin-fixed, paraffin-embedded sections (5 μm) were processed for immunohistochemistry as previously described, 9,10 using antibodies against human PD-L1 
| Evaluation of immunohistochemical staining
Tissue sections were analyzed by two independent pathologists blinded to clinicopathological and survival data. PD-L1 expression was evaluated on TC and IC as reported in recent trials. 17, 27 An isotype control was used as negative control for signal detection and 
| Statistical analysis
Statistical analyses were carried out using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). Differences between groups were determined using the Wilcoxon signed-rank test. Cumulative survival time was calculated using the Kaplan-Meier method and compared using the log-rank test. A multivariate Cox proportional hazards model was used to estimate adjusted hazard ratios and 95% CI and identify independent prognostic factors. PD-L1-positivity was defined as ≥5% PD-L1 + TC or IC. For categorical analyses, median value was used as a cut-off to dichotomize continuous variables (for clinical applications). Two-tailed P-values <.05 were considered significant.
| RE SULTS
| Programmed death ligand-1 expression in resectable UCB
Programmed death ligand-1 expression was clearly observed in the cell membranes of the 248 resectable UCB specimens, with variable cytoplasmic staining in TC and/or IC ( Figure 1 ). PD-L1 IHC score distribution was 0 (183, 74%), 1 (7, 3%), 2 (15, 6%) and 3 (43, 17%) for TC and 0 (90, 36%), 1 (22, 9%), 2 (48, 19%) and 3 (88, 36%) for IC. were adopted as covariates in multivariate analysis (Table 2) , which
showed that PD-L1 + IC was an independent prognostic factor for OS (HR: 3.02, P = .001) and RFS (HR: 1.858, P = .024).
We further evaluated the prognostic value of PD-L1 expression in subgroups of patients stratified by tumor stage ( Figure S2 ). PD-L1 + IC maintained prognostic value for shorter OS and RFS, except for RFS in non-muscle-invasive bladder cancer (NMIBC, tumor stage Ta+T1, P = .24).
We also evaluated the combined influence of PD-L1 + TC plus PD-L1 + IC on patient outcomes using the Wald test for interaction confirmed that the differences in OS and RFS between groups I and III were significant (P = .007 and P = .002, respectively; Table S2 ).
These data clearly show a strong association between PD-L1 expression and poorer survival in resectable UCB. field, respectively; Figure 3B ,D; n = 77). Thus, both CD8 + TIL and T-bet + TIL are biased towards stromal localization in UCB.
| Associations between PD-L1
Correlation between stromal TIL density and clinicopathological variables, including PD-L1 expression, was evaluated by χ 2 analysis.
There was a positive correlation between CD8 ST + TIL density and age (P = .02), tumor size (P = .007), tumor stage (P < .001), nodal status (P = .002) and histological grade (P < .001). T-bet ST + TIL cell density was positively associated with tumor stage (P < .001) and histological grade (P = .002; Table S3 ). Moreover, CD8 ST + TIL and Tbet ST + TIL densities were both positively associated with PD-L1 + TC (P < .0001 and P = .004; Figure 4A ,C) and PD-L1 + IC (both P < .0001; Figure 4B ,D).
Kaplan-Meier analysis showed a negative association between CD8 ST + TIL density and OS (P < .001), but not RFS (P = .99; Figure   S3a ). Patients with high CD8 ST + TIL density had shorter OS than patients with low CD8 ST + TIL density (median, 48 vs 59 months). These results were identical to our previous results. 13 However, T-bet ST + TIL density was not associated with OS or RFS (P > .05; Figure S3b ). 
TC and PD-L1
+ IC with high CD8 ST + TIL (n = 18). OS was significantly different (P = 0.002), and a trend towards a significant difference in recurrence was observed between groups I and III (P = .086; Figure   S4 ).
| Associations between PD-1 + TIL and PD-L1
+
IC, CD8 + TIL and clinical outcomes
The known receptor for PD-L1 is PD-1, a key immunosuppressive marker expressed on exhausted TIL, which may be responsible for the poor outcome of higher CD8 ST + TIL density for UCB patients.
28
To test the hypothesis, distribution and clinical significance of PD- Kaplan-Meier analysis showed a negative association between PD-1 ST + TIL density and OS (P = .0013; Figure 5C ). Moreover, PD-1 ST + TIL density was significantly positively associated with PD-L1 + IC (P < .0001; Figure 5D ) and CD8 ST + TIL density (P < .0001; Figure 5E ). 
| D ISCUSS I ON
PD-L1
+ IC comprised diverse immune cell compositions with different intensities and variably sized aggregates in stroma of the same tissues, which made it more difficult to determine for intensities of PD-L1 expression by different cellular resources. We now know that the effects of PD-L1 can induce T-cell dysfunction through a variety of mechanisms, including the induction of T-cell apoptosis and exhaustion or regulation of IL-10 expression and Treg functions. [29] [30] [31] [32] Therefore, the variable levels of PD-L1 expression in stromal cells might reflect their potentially different functions on tumor immune suppression. Programmed death ligand-1 expression in the tumor microenvironment is thought to be regulated by tumor-associated stroma (adaptive immune resistance) and/or tumor cells (intrinsic immune resistance). 16 According to the "adaptive resistance" hypothesis, PD-L1 is upregulated by the effector molecule INF-γ in the tumor niche and, then, the PD pathway serves as a negative feedback mechanism to suppress tumor immunity. Accumulating evidence has shown that high memory T-cell density is associated with longer OS in human cancers. 8 However,
TA B L E 2
we found that a high stromal CD8 + T-cell density was associated with poorer OS in patients with resectable UCB; Continued clinical development of PD1/PD-L1 checkpoint inhibitors may be effective for all pathological stages of UCB.
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